Pharma BD Deal Intelligence
Sanofi acquired Kymab for $1.45B for KY1005 autoimmune candidate.
Amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis (EASI-75 35.9-39.1% vs…
Amlitelimab confirms potential in atopic dermatitis: SHORE met all primary/key secondary endpoints; COAST 2 met US co-primary but missed EU co-primary. Sanofi…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sanofi acquired UK-based Kymab for up to $1.45B ($1.1B upfront in cash plus up to $350M in milestones; deal closed April 2021), gaining KY1005 - now amlitelimab, a fully human anti-OX40L monoclonal antibody for atopic dermatitis and other immune-mediated diseases. The acquisition rationale - building Sanofi's immunology pipeline beyond Dupixent with a differentiated, non-JAK, non-IL-4/13 mechanism - has since been validated by the pivotal OCEANA Phase 3 program: COAST 1 (Sep 2025) and SHORE (Jan 2026) met all primary and key secondary endpoints in moderate-to-severe atopic dermatitis, while COAST 2 met its US co-primary endpoint but missed the EU co-primary. On the totality of data Sanofi announced it will pursue global regulatory submissions, with filings planned for H2 2026; the AQUA and ESTUARY Phase 3 studies are expected to read out in H2 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Kymab Ltd (this deal) | 2021 | $1.4B | 53 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2021 deals · Sanofi SA deals · Dermatology deals